{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T02:56:04Z","timestamp":1785293764577,"version":"3.55.0"},"reference-count":67,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,5,12]],"date-time":"2025-05-12T00:00:00Z","timestamp":1747008000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p>Due to the potential occurrence of drug interactions, the combined application of firmonertinib and paxlovid carries a relatively high risk. Nevertheless, as of now, there has been no comprehensive research on the interaction between firmonertinib and paxlovid. Our aim was to establish and validate an accurate, stable, rapid and simple UPLC-MS\/MS method for the simultaneous determination of firmonertinib and its metabolite AST-5902 in rat plasma, which was applied to the study of the <jats:italic>in vivo<\/jats:italic> interaction between firmonertinib and paxlovid. Gefitinib was selected as the internal standard. After protein precipitation of the plasma samples with acetonitrile, the separation was carried out on a Shimadzu LC-20AT UHPLC. The chromatographic column was a Shim-pack Volex PFPP column (50\u00a0mm \u00d7 2.1\u00a0mm, 1.8\u00a0\u03bcm), and the mobile phase was composed of 0.1% formic acid - water and 0.1% formic acid - methanol. Mass spectrometry detection was performed using a Shimadzu 8,040 mass spectrometer in ESI+ and MRM mode. The precision, accuracy, recovery and matrix effect of this method were detected. The linearity of the method and the stability of the samples were assessed. Subsequently, the method was applied to the study of the interaction between firmonertinib and paxlovid. The parent ions and typical fragment ions of firmonertinib, AST-5902 and IS are respectively m\/z 569.25 \u2192 72.15, m\/z 555.50 \u2192 498.10 and m\/z 447.25\u2192 128.20. The selectivity, specificity, linearity, recovery, matrix effect, accuracy and precision of the method and the stability of the samples were all adequately verified. The results of drug interaction showed that when firmonertinib was combined with paxlovid, the AUC and Cmax of firmonertinib were significantly increased, while the AUC, Tmax, and Cmax of AST-5902 were significantly decreased. The established UHPLC-MS\/MS detection method is accurate, stable, rapid and simple. Paxlovid exhibit a significant inhibitory effect on the metabolism of firmonertinib in rats.<\/jats:p>","DOI":"10.3389\/fphar.2025.1570206","type":"journal-article","created":{"date-parts":[[2025,5,12]],"date-time":"2025-05-12T04:13:39Z","timestamp":1747023219000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Development and application of a UHPLC-MS\/MS method for the simultaneous determination of firmonertinib and its main metabolite AST-5902 in rat plasma: a study on the in vivo drug interaction between firmonertinib and paxlovid"],"prefix":"10.3389","volume":"16","author":[{"given":"Peng-Fei","family":"Tang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Su-Su","family":"Bao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei-Fei","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhong-Xiang","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xue-Meng","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong-Lei","family":"Ge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,5,12]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"102041","DOI":"10.1016\/j.ctrv.2020.102041","article-title":"Cancer and COVID-19: unmasking their ties","volume":"88","author":"Addeo","year":"2020","journal-title":"Cancer Treat. Rev."},{"key":"B2","doi-asserted-by":"publisher","first-page":"e28441","DOI":"10.1002\/jmv.28441","article-title":"Efficacy and safety of nirmatrelvir\/ritonavir (Paxlovid) for COVID-19: a rapid review and meta-analysis","volume":"95","author":"Amani","year":"2023","journal-title":"J. Med. Virol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"100452","DOI":"10.1016\/j.jtocrr.2022.100452","article-title":"Overview of drug-drug interactions between ritonavir-boosted nirmatrelvir (paxlovid) and targeted therapy and supportive care for lung cancer","volume":"4","author":"Anwar","year":"2023","journal-title":"JTO Clin. Res. Rep."},{"key":"B4","doi-asserted-by":"publisher","first-page":"217","DOI":"10.3390\/pharmaceutics16020217","article-title":"The design, synthesis and mechanism of action of paxlovid, a protease inhibitor drug combination for the treatment of COVID-19","volume":"16","author":"Bege","year":"2024","journal-title":"Pharmaceutics"},{"key":"B5","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1007\/s11095-022-03244-8","article-title":"Ritonavir-boosted exposure of kinase inhibitors: an open label, cross-over pharmacokinetic proof-of-concept trial with erlotinib","volume":"39","author":"Boosman","year":"2022","journal-title":"Pharm. Res."},{"key":"B6","doi-asserted-by":"publisher","first-page":"1212313","DOI":"10.3389\/fphar.2023.1212313","article-title":"Comparison of the efficacy and safety of first-line treatments for of advanced EGFR mutation-positive non-small-cell lung cancer in Asian populations: a systematic review and network meta-analysis","volume":"14","author":"Chen","year":"2023","journal-title":"Front. Pharmacol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1158\/2159-8290.Cd-20-0422","article-title":"Patients with cancer appear more vulnerable to SARS-CoV-2: a multicenter study during the COVID-19 outbreak","volume":"10","author":"Dai","year":"2020","journal-title":"Cancer Discov."},{"key":"B8","doi-asserted-by":"publisher","first-page":"1357913","DOI":"10.3389\/fphar.2024.1357913","article-title":"Furmonertinib for EGFR-mutant advanced non-small cell lung cancer: a glittering diamond in the rough of EGFR-TKI","volume":"15","author":"Ding","year":"2024","journal-title":"Front. Pharmacol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"100794","DOI":"10.1016\/j.drup.2021.100794","article-title":"An update on drugs with therapeutic potential for SARS-CoV-2 (COVID-19) treatment","volume":"59","author":"Dro\u017cd\u017cal","year":"2021","journal-title":"Drug Resist Updat."},{"key":"B10","doi-asserted-by":"publisher","first-page":"e143","DOI":"10.1016\/s2666-7568(22)00009-5","article-title":"Geriatric risk factors for serious COVID-19 outcomes among older adults with cancer: a cohort study from the COVID-19 and Cancer Consortium","volume":"3","author":"Elkrief","year":"2022","journal-title":"Lancet Healthy Longev."},{"key":"B11","unstructured":"Bioanalytical method validation guidance for industry\n          \n          \n          2018"},{"key":"B12","doi-asserted-by":"publisher","first-page":"648","DOI":"10.3389\/fonc.2020.00648","article-title":"Coronavirus: older persons with cancer in Italy in the COVID-19 pandemic","volume":"10","author":"Fratino","year":"2020","journal-title":"Front. Oncol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1016\/s1470-2045(20)30314-4","article-title":"COVID-19 in patients with thoracic malignancies (TERAVOLT): first results of an international, registry-based, cohort study","volume":"21","author":"Garassino","year":"2020","journal-title":"Lancet Oncol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"1212","DOI":"10.1124\/dmd.117.079038","article-title":"The drug-drug interaction potential of antiviral agents for the treatment of chronic hepatitis C infection","volume":"46","author":"Garrison","year":"2018","journal-title":"Drug Metab. Dispos."},{"key":"B15","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1007\/s00059-023-05183-5","article-title":"The COVID-19 pandemic in China: from dynamic zero-COVID to current policy","volume":"48","author":"Ge","year":"2023","journal-title":"Herz"},{"key":"B16","doi-asserted-by":"publisher","first-page":"2000547","DOI":"10.1183\/13993003.00547-2020","article-title":"Comorbidity and its impact on 1590 patients with COVID-19 in China: a nationwide analysis","volume":"55","author":"Guan","year":"2020","journal-title":"Eur. Respir. J."},{"key":"B17","doi-asserted-by":"publisher","first-page":"105815","DOI":"10.1016\/j.ejps.2021.105815","article-title":"Evaluation of the pharmacokinetic effects of itraconazole on alflutinib (AST2818): an open-label, single-center, single-sequence, two-period randomized study in healthy volunteers","volume":"162","author":"Heng","year":"2021","journal-title":"Eur. J. Pharm. Sci."},{"key":"B18","doi-asserted-by":"publisher","first-page":"3000605241281907","DOI":"10.1177\/03000605241281907","article-title":"Risk of COVID-19 infection in patients with NSCLC receiving EGFR-TKI targeted therapy during the first wave in China","volume":"52","author":"Huang","year":"2024","journal-title":"J. Int. Med. Res."},{"key":"B19","doi-asserted-by":"publisher","first-page":"499","DOI":"10.5578\/tt.20219608","article-title":"Clinical characteristics of lung cancer patients with COVID-19: retrospective case series","volume":"69","author":"Kahya","year":"2021","journal-title":"Tuberk. Toraks"},{"key":"B20","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1186\/s12885-022-09649-3","article-title":"A comprehensive evaluation of potentially significant drug-drug, drug-herb, and drug-food interactions among cancer patients receiving anticancer drugs","volume":"22","author":"Koni","year":"2022","journal-title":"BMC Cancer"},{"key":"B21","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1007\/s40265-022-01692-5","article-title":"Nirmatrelvir plus ritonavir: first approval","volume":"82","author":"Lamb","year":"2022","journal-title":"Drugs"},{"key":"B22","doi-asserted-by":"publisher","first-page":"541","DOI":"10.2165\/00003495-199652040-00007","article-title":"Ritonavir","volume":"52","author":"Lea","year":"1996","journal-title":"Drugs"},{"key":"B23","doi-asserted-by":"publisher","first-page":"99","DOI":"10.3390\/biom14010099","article-title":"A review of CYP-mediated drug interactions: mechanisms and in vitro drug-drug interaction assessment","volume":"14","author":"Lee","year":"2024","journal-title":"Biomolecules"},{"key":"B24","doi-asserted-by":"publisher","first-page":"106564","DOI":"10.1016\/j.ejps.2023.106564","article-title":"Drug-drug interactions and dose management of BTK inhibitors when initiating nirmatrelvir\/ritonavir (paxlovid) based on physiologically-based pharmacokinetic models","volume":"189","author":"Li","year":"2023","journal-title":"Eur. J. Pharm. Sci."},{"key":"B25","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1016\/j.jad.2023.05.055","article-title":"The negative impact of loneliness and perceived stress on mental health during two-month lockdown in Shanghai","volume":"335","author":"Li","year":"2023","journal-title":"J. Affect Disord."},{"key":"B26","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1016\/s1470-2045(20)30096-6","article-title":"Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China","volume":"21","author":"Liang","year":"2020","journal-title":"Lancet Oncol."},{"key":"B27","doi-asserted-by":"publisher","first-page":"112735","DOI":"10.1016\/j.jpba.2019.06.032","article-title":"Simultaneous determination of alflutinib and its active metabolite in human plasma using liquid chromatography-tandem mass spectrometry","volume":"176","author":"Liu","year":"2019","journal-title":"J. Pharm. Biomed. Anal."},{"key":"B28","doi-asserted-by":"publisher","first-page":"1366","DOI":"10.1038\/s41401-020-0389-3","article-title":"Alflutinib (AST2818), primarily metabolized by CYP3A4, is a potent CYP3A4 inducer","volume":"41","author":"Liu","year":"2020","journal-title":"Acta Pharmacol. Sin."},{"key":"B29","doi-asserted-by":"publisher","first-page":"1822","DOI":"10.1016\/j.transproceed.2023.07.007","article-title":"Effect of paxlovid on tacrolimus concentration in perioperative kidney transplant patients infected with COVID-19: a case report","volume":"55","author":"Liu","year":"2023","journal-title":"Transpl. Proc."},{"key":"B30","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1200\/cci.20.00068","article-title":"Effects of the COVID-19 pandemic on cancer-related patient encounters","volume":"4","author":"London","year":"2020","journal-title":"JCO Clin. Cancer Inf."},{"key":"B31","doi-asserted-by":"publisher","first-page":"7341493","DOI":"10.1155\/2022\/7341493","article-title":"Paxlovid: mechanism of action, synthesis, and in silico study","volume":"2022","author":"Marzi","year":"2022","journal-title":"Biomed. Res. Int."},{"key":"B32","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.1002\/cpt.2646","article-title":"Recommendations for the management of drug-drug interactions between the COVID-19 antiviral nirmatrelvir\/ritonavir (paxlovid) and comedications","volume":"112","author":"Marzolini","year":"2022","journal-title":"Clin. Pharmacol. Ther."},{"key":"B33","first-page":"25","article-title":"Drug prescribing: drug-drug interactions","volume":"508","author":"McQuade","year":"2021","journal-title":"FP Essent."},{"key":"B34","doi-asserted-by":"publisher","first-page":"5","DOI":"10.3892\/mco.2020.2075","article-title":"[Comment] Ethical and practical considerations on cancer recommendations during COVID-19 pandemic","volume":"13","author":"Melidis","year":"2020","journal-title":"Mol. Clin. Oncol."},{"key":"B35","doi-asserted-by":"publisher","first-page":"1106","DOI":"10.21037\/jtd-22-1091","article-title":"Narrowing the therapeutic window? A case-control study on the influence of the COVID-19 pandemic on the primary UICC stage of NSCLC","volume":"15","author":"Metelmann","year":"2023","journal-title":"J. Thorac. Dis."},{"key":"B36","doi-asserted-by":"publisher","first-page":"e35489","DOI":"10.7759\/cureus.35489","article-title":"Paxlovid-induced tacrolimus toxicity in the treatment of COVID-19: a case report","volume":"15","author":"Michael","year":"2023","journal-title":"Cureus"},{"key":"B37","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.1016\/j.annonc.2020.04.006","article-title":"Do patients with cancer have a poorer prognosis of COVID-19? An experience in New York City","volume":"31","author":"Miyashita","year":"2020","journal-title":"Ann. Oncol."},{"key":"B38","doi-asserted-by":"publisher","first-page":"662746","DOI":"10.3389\/fonc.2021.662746","article-title":"More severe COVID-19 in patients with active cancer: results of a multicenter cohort study","volume":"11","author":"Monari","year":"2021","journal-title":"Front. Oncol."},{"key":"B39","doi-asserted-by":"publisher","first-page":"e342","DOI":"10.1093\/cid\/ciac443","article-title":"Effectiveness of paxlovid in reducing severe coronavirus disease 2019 and mortality in high-risk patients","volume":"76","author":"Najjar-Debbiny","year":"2023","journal-title":"Clin. Infect. Dis."},{"key":"B40","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1007\/s00228-010-0879-1","article-title":"Oxycodone concentrations are greatly increased by the concomitant use of ritonavir or lopinavir\/ritonavir","volume":"66","author":"Nieminen","year":"2010","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"B41","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1007\/s42977-023-00156-5","article-title":"Learning from cancer to address COVID-19","volume":"74","author":"Ol\u00e1h","year":"2023","journal-title":"Biol. Futur"},{"key":"B42","doi-asserted-by":"publisher","first-page":"e156","DOI":"10.1055\/s-0043-1777856","article-title":"Short-term outcomes of COVID-19 pandemic on non-small cell lung cancer screening and management","volume":"9","author":"Orelaru","year":"2023","journal-title":"Surg. J. (N Y)"},{"key":"B43","doi-asserted-by":"publisher","first-page":"e935952","DOI":"10.12659\/msm.935952","article-title":"Editorial: current status of oral antiviral drug treatments for SARS-CoV-2 infection in non-hospitalized patients","volume":"28","author":"Parums","year":"2022","journal-title":"Med. Sci. Monit."},{"key":"B44","doi-asserted-by":"publisher","first-page":"100124","DOI":"10.1016\/j.jtocrr.2020.100124","article-title":"Coronavirus disease 2019 infection in a patient population with lung cancer: incidence, presentation, and alternative diagnostic considerations","volume":"2","author":"Piper-Vallillo","year":"2021","journal-title":"JTO Clin. Res. Rep."},{"key":"B45","doi-asserted-by":"publisher","first-page":"1557","DOI":"10.1016\/j.transproceed.2022.04.015","article-title":"Paxlovid (Nirmatelvir\/Ritonavir) and tacrolimus drug-drug interaction in a kidney transplant patient with SARS-2-CoV infection: a case report","volume":"54","author":"Prikis","year":"2022","journal-title":"Transpl. Proc."},{"key":"B46","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/j.lungcan.2021.05.014","article-title":"Lung cancer patients with COVID-19 in Spain: GRAVID study","volume":"157","author":"Provencio","year":"2021","journal-title":"Lung Cancer"},{"key":"B47","doi-asserted-by":"publisher","first-page":"236","DOI":"10.37201\/req\/002.2022","article-title":"Nirmatrelvir plus ritonavir (Paxlovid) a potent SARS-CoV-2 3CLpro protease inhibitor combination","volume":"35","author":"Reina","year":"2022","journal-title":"Rev. Esp. Quimioter."},{"key":"B48","doi-asserted-by":"publisher","first-page":"2052","DOI":"10.1001\/jama.2020.6775","article-title":"Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York city area","volume":"323","author":"Richardson","year":"2020","journal-title":"Jama"},{"key":"B49","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1097\/coc.0000000000000865","article-title":"The impact of COVID-19 on patients with cancer: a national study of patient experiences","volume":"44","author":"Rodriguez","year":"2021","journal-title":"Am. J. Clin. Oncol."},{"key":"B50","doi-asserted-by":"publisher","first-page":"103159","DOI":"10.1016\/j.jbi.2019.103159","article-title":"A comprehensive review of feature based methods for drug target interaction prediction","volume":"93","author":"Sachdev","year":"2019","journal-title":"J. Biomed. Inf."},{"key":"B51","doi-asserted-by":"publisher","first-page":"e13833","DOI":"10.1111\/1467-9566.13833","article-title":"Disputes over the figures of the COVID-19 pandemic: epistemic diversity, dissemination of science, and political opposition","volume":"47","author":"Sarrazin","year":"2025","journal-title":"Sociol. Health Illn."},{"key":"B52","doi-asserted-by":"publisher","first-page":"1967","DOI":"10.1002\/ijc.34868","article-title":"Patient-reported outcomes in advanced NSCLC before and during the COVID-19 pandemic: real-world data from the German prospective CRISP Registry (AIO-TRK-0315)","volume":"154","author":"Sebastian","year":"2024","journal-title":"Int. J. Cancer"},{"key":"B53","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1016\/s2213-2600(22)00168-0","article-title":"Furmonertinib (AST2818) versus gefitinib as first-line therapy for Chinese patients with locally advanced or metastatic EGFR mutation-positive non-small-cell lung cancer (FURLONG): a multicentre, double-blind, randomised phase 3 study","volume":"10","author":"Shi","year":"2022","journal-title":"Lancet Respir. Med."},{"key":"B54","doi-asserted-by":"publisher","first-page":"e2381","DOI":"10.1002\/rmv.2381","article-title":"Evolution of the SARS-CoV-2 omicron variants BA.1 to BA.5: implications for immune escape and transmission","volume":"32","author":"Shrestha","year":"2022","journal-title":"Rev. Med. Virol."},{"key":"B55","doi-asserted-by":"publisher","first-page":"960311","DOI":"10.3389\/fphar.2022.960311","article-title":"Development and validation of a UHPLC-MS\/MS method for quantitation of almonertinib in rat plasma: application to an in vivo interaction study between paxlovid and almonertinib","volume":"13","author":"Tang","year":"2022","journal-title":"Front. Pharmacol."},{"key":"B56","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1038\/s41576-021-00408-x","article-title":"The biological and clinical significance of emerging SARS-CoV-2 variants","volume":"22","author":"Tao","year":"2021","journal-title":"Nat. Rev. Genet."},{"key":"B57","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1136\/postgradmedj-2020-138234","article-title":"Origin, transmission, diagnosis and management of coronavirus disease 2019 (COVID-19)","volume":"96","author":"Umakanthan","year":"2020","journal-title":"Postgrad. Med. J."},{"key":"B58","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1001\/jamainternmed.2020.0994","article-title":"Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China","volume":"180","author":"Wu","year":"2020","journal-title":"JAMA Intern Med."},{"key":"B59","doi-asserted-by":"publisher","first-page":"8686","DOI":"10.1021\/acs.jmedchem.2c00404","article-title":"Evolutionary and structural insights about potential SARS-CoV-2 evasion of nirmatrelvir","volume":"65","author":"Yang","year":"2022","journal-title":"J. Med. Chem."},{"key":"B60","doi-asserted-by":"publisher","first-page":"493","DOI":"10.2174\/1389200224666230418093139","article-title":"Pharmacokinetic drug-drug interactions involving antiretroviral agents: an update","volume":"24","author":"Yu","year":"2023","journal-title":"Curr. Drug Metab."},{"key":"B61","doi-asserted-by":"publisher","first-page":"1125246","DOI":"10.3389\/fimmu.2023.1125246","article-title":"The development of COVID-19 treatment","volume":"14","author":"Yuan","year":"2023","journal-title":"Front. Immunol."},{"key":"B62","doi-asserted-by":"publisher","first-page":"928983","DOI":"10.3389\/fphar.2022.928983","article-title":"Instability mechanism of osimertinib in plasma and a solving strategy in the pharmacokinetics study","volume":"13","author":"Yuan","year":"2022","journal-title":"Front. Pharmacol."},{"key":"B63","doi-asserted-by":"publisher","first-page":"894","DOI":"10.1016\/j.annonc.2020.03.296","article-title":"Clinical characteristics of COVID-19-infected cancer patients: a retrospective case study in three hospitals within Wuhan, China","volume":"31","author":"Zhang","year":"2020","journal-title":"Ann. Oncol."},{"key":"B64","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1186\/s40001-022-00927-1","article-title":"Analysis of 394 COVID-19 cases infected with Omicron variant in Shenzhen: impact of underlying diseases to patient\u2019s symptoms","volume":"27","author":"Zhang","year":"2022","journal-title":"Eur. J. Med. Res."},{"key":"B65","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.1016\/s0140-6736(20)30566-3","article-title":"Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study","volume":"395","author":"Zhou","year":"2020","journal-title":"Lancet"},{"key":"B66","doi-asserted-by":"publisher","first-page":"310","DOI":"10.2174\/138920008784220664","article-title":"Drugs behave as substrates, inhibitors and inducers of human cytochrome P450 3A4","volume":"9","author":"Zhou","year":"2008","journal-title":"Curr. Drug Metab."},{"key":"B67","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1007\/s10637-021-01071-z","article-title":"Effects of rifampicin on the pharmacokinetics of alflutinib, a selective third-generation EGFR kinase inhibitor, and its metabolite AST5902 in healthy volunteers","volume":"39","author":"Zhu","year":"2021","journal-title":"Invest. New Drugs"}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2025.1570206\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,12]],"date-time":"2025-05-12T04:13:41Z","timestamp":1747023221000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2025.1570206\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,12]]},"references-count":67,"alternative-id":["10.3389\/fphar.2025.1570206"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2025.1570206","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,12]]},"article-number":"1570206"}}